{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:03:11Z","timestamp":1785542591335,"version":"3.56.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic kidney disease (CKD) in heart failure (HF) patients is common, present in 49%, and is associated with a higher mortality hazard ratio [2.34 (95% confidence interval 2.20\u20132.50); P\u2009&amp;lt;\u20090.001] and multiple hospital admissions. The management of HF in CKD can be challenging due to drug-induced electrolyte and creatinine changes, resistance to diuretics and infections related to device therapy. Evidence for improvement in mortality and HF hospitalizations exists in HF with reduced ejection fraction (HFrEF) in Stage 3 CKD patients from randomized controlled trials of angiotensin-converting enzyme inhibitor (ACEi) and mineralocorticoid receptor antagonist therapy but not in dialysis patients, where higher doses can cause hyperkalaemia. Evidence of improvement in cardiovascular death and HF hospitalizations has emerged with the angiotensin receptor neprilysin inhibitor ivabradine and more recently with sodium\u2013glucose cotransporter inhibitors in HFrEF patients with CKD Stages 1\u20133. However, these studies have excluded CKD Stages 4 and 5 patients. Evidence for \u03b2-blocker therapy exists in CKD Stages 1\u20133 and separately in haemodialysis patients. Cardiac resynchronization therapy reduces HF hospitalizations and mortality in patients with CKD Stages 1\u20133 but has not been shown to do so in CKD Stages 4 and 5 or dialysis patients. Internal cardioverter and defibrillator therapy in HFrEF patients has been shown to be beneficial in CKD 3 patients but not in dialysis patients, where it is associated with high rates of infection. For HFpEF patients with CKD, therapy is symptomatic, as there is no proven therapy for improvement in survival or hospitalizations. HF patients with end-stage kidney disease with fluid overload may benefit from peritoneal dialysis. A multidisciplinary, personalized approach has been associated with better care and improved patient satisfaction.<\/jats:p>","DOI":"10.1093\/ndt\/gfab026","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:24:40Z","timestamp":1613161480000},"page":"2055-2062","source":"Crossref","is-referenced-by-count":18,"title":["Personalizing heart failure management in chronic kidney disease patients"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-2325","authenticated-orcid":false,"given":"Debasish","family":"Banerjee","sequence":"first","affiliation":[{"name":"Renal and Transplantation Unit, St George\u2019s University Hospitals NHS Foundation Trust , London, UK"},{"name":"Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George\u2019s, University of London , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Yee-Moon","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, University of Hong Kong , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2022102109173468900_gfab026-B1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102109173468900_gfab026-B2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ehf2.12185","article-title":"Impaired renal function affects clinical outcomes and management of patients with heart failure","volume":"4","author":"Jenkins","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2022102109173468900_gfab026-B3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2022102109173468900_gfab026-B4","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102109173468900_gfab026-B5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B6","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Diuretic therapy for patients with heart dailure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102109173468900_gfab026-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2022102109173468900_gfab026-B8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"key":"2022102109173468900_gfab026-B9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD","year":"1991","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2022102109173468900_gfab026-B13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2009.457","article-title":"Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"Flynn","year":"2009","journal-title":"JAMA"},{"key":"2022102109173468900_gfab026-B14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2022102109173468900_gfab026-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2022102109173468900_gfab026-B16","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2022102109173468900_gfab026-B18","first-page":"CD012466","article-title":"Pharmacological interventions for heart failure in people with chronic kidney disease","volume":"2","author":"Lunney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2022102109173468900_gfab026-B19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022102109173468900_gfab026-B20","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102109173468900_gfab026-B21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. the SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Nephrol"},{"key":"2022102109173468900_gfab026-B23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109173468900_gfab026-B24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"2022102109173468900_gfab026-B25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B26","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022102109173468900_gfab026-B27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2022102109173468900_gfab026-B28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2022102109173468900_gfab026-B29","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"2022102109173468900_gfab026-B30","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102109173468900_gfab026-B31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/eurjhf\/hft060","article-title":"Venous congestion and renal function in heart failure \u2026 it's complicated","volume":"15","author":"Testani","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2022102109173468900_gfab026-B33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/00015385.2018.1455947","article-title":"Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome","volume":"74","author":"Verbrugge","year":"2019","journal-title":"Acta Cardiol"},{"key":"2022102109173468900_gfab026-B34","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"2022102109173468900_gfab026-B35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B36","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1002\/ehf2.12974","article-title":"Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022102109173468900_gfab026-B37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2022102109173468900_gfab026-B38","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B40","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/CIRCULATIONAHA.119.039818","article-title":"Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients","volume":"139","author":"Jukema","year":"2019","journal-title":"Circulation"},{"key":"2022102109173468900_gfab026-B41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"2022102109173468900_gfab026-B42","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102109173468900_gfab026-B43","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/ehf2.12796","article-title":"Management and outcomes of heart failure patients with CKD: experience from an inter-disciplinary clinic","volume":"7","author":"Nguyen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022102109173468900_gfab026-B44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7861\/futurehosp.6-1-s104","article-title":"The scope of a combined kidney failure-heart failure clinic","volume":"6","author":"Lowe-Jones","year":"2019","journal-title":"Future Healthc J"},{"key":"2022102109173468900_gfab026-B45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/qjmed\/89.9.681","article-title":"Long-term successful management of refractory congestive cardiac failure by intermittent ambulatory peritoneal ultrafiltration","volume":"89","author":"Tormey","year":"1996","journal-title":"QJM"},{"key":"2022102109173468900_gfab026-B46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3747\/pdi.2012.00290","article-title":"Peritoneal ultrafiltration in refractory heart failure: a cohort study","volume":"34","author":"Bertoli","year":"2014","journal-title":"Perit Dial Int"},{"key":"2022102109173468900_gfab026-B47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ndt\/gfp484","article-title":"Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure","volume":"25","author":"S\u00e1nchez","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2022102109173468900_gfab026-B48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ckj\/sfv007","article-title":"Peritoneal ultrafiltration in end-stage chronic heart failure","volume":"8","author":"Fr\u00f6hlich","year":"2015","journal-title":"Clin Kidney J"},{"key":"2022102109173468900_gfab026-B49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40620-014-0166-9","article-title":"Peritoneal ultrafiltration in congestive heart failure-findings reported from its application in clinical practice: a systematic review","volume":"28","author":"Viglino","year":"2015","journal-title":"J Nephrol"},{"key":"2022102109173468900_gfab026-B50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0896860819895198","article-title":"The use of peritoneal dialysis in heart failure: a systematic review","volume":"40","author":"Chionh","year":"2020","journal-title":"Perit Dial Int"},{"key":"2022102109173468900_gfab026-B51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3747\/pdi.2018.00272","article-title":"Peritoneal ultrafiltration for heart failure: lessons from a randomized controlled trial","volume":"39","author":"Dukka","year":"2019","journal-title":"Perit Dial Int"},{"key":"2022102109173468900_gfab026-B52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11255-012-0147-7","article-title":"Use of peritoneal ultrafiltration in the elderly refractory congestive heart failure patients","volume":"44","author":"Ruhi","year":"2012","journal-title":"Int Urol Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab026\/41928534\/gfab026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/11\/2055\/46585836\/gfab026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/11\/2055\/46585836\/gfab026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:20:10Z","timestamp":1666344010000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/11\/2055\/6137842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2022,10,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab026","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2021,2,16]]}}}